Given the inhibitory role of FGF19 in endochondral ossification, targeting the FGF19-FGFR4-β-catenin pathway presents a promising strategy for treating skeletal growth disorders characterized by growth plate dysfunction, such as idiopathic short stature and certain chondrodysplasias. The gene discussed is FGF19; the disease is chondrodysplasia.